What happened
The Lancet published REMODEL-1 and REMODEL-2 results on 23 October 2026. Adults with relapsing multiple sclerosis received remibrutinib 100 mg twice daily or teriflunomide 14 mg daily. The PubMed article abstract reports annualised relapse rates of 0.073 versus 0.112 in REMODEL-1 (rate ratio 0.648, 95% CI 0.453–0.927) and 0.080 versus 0.116 in REMODEL-2 (0.688, 0.487–0.972). The abstract reports common adverse events and fewer adverse-event-related treatment discontinuations with remibrutinib (3.1% versus 5.8%) and says there were no liver safety concerns. In its 23 October announcement, Novartis reports rises in the liver enzyme ALT above three times the normal limit in 2.0% of people on remibrutinib versus 7.4% on teriflunomide across both trials, and no Hy's Law cases with remibrutinib (a pattern that can signal serious drug-related liver injury); a 29.2% lower risk of disability worsening confirmed as lasting at least 6 months; and 65% and 70% lower T2 lesion activity on MRI in the two trials. These figures are the company's; the full paper and its safety appendix were not reviewed here. These RMS trials are distinct from the separate REMASTER trial in secondary progressive MS.
What this means for people with MS
The two trials support a relapse-rate benefit relative to teriflunomide in the studied RMS population. They do not by themselves establish individual benefit, superiority to every available therapy or prevention of disability progression. The company describes the disability result as nominally significant, so it is not a confirmed finding; these figures cannot be compared directly with other BTK inhibitors. Teriflunomide itself commonly raises liver enzymes, so fewer rises than with it do not show that remibrutinib carries no liver risk. ClinicalTrials.gov currently lists both REMODEL studies as active without taking new participants.
- What kind of evidence exists?
- Two masked, active-comparator trials; 2,007 adults randomised across 407 centres in 46 countries
- How reliable is this source?
- Peer-reviewed primary Lancet article abstract and official PubMed metadata reviewed; the Novartis announcement was read for the liver, disability and MRI figures; full paper and safety appendices were inaccessible in this review. Official NCT05147220 and NCT05156281 records checked separately for current status and locations.
- Research event/source date
- Published by MyelinWatch
- Last substantive MyelinWatch update